Transportan 10 improves the anticancer activity of cisplatin

• DOI: 10.1007/s00210-016-1219-5
• Publication Date: 2016-02-22T01:32:00Z
• Authors: Rusiecka Izabela; Ruczyński Jarosław; Alenowicz Magdalena; Rekowski Piotr; Kocić Ivan
• Keywords: HeLa; MTT assay; Viability assay

The aim of this paper was to examine whether cell-penetrating peptides (CPPs) such as transportan 10 (TP10) or protein transduction domain (PTD4) may improve the anticancer activity cisplatin (cPt). complexes TP10 PTD4 with cPt were used in experiments. They carried out on two non-cancer (HEK293 (human embryonic kidney) and HEL299 embryo lung)) cancer (HeLa cervical cancer) OS143B osteosarcoma 143B)) cell lines. Both tested (MTT assay) respect their cytotoxic actions. TAMRA (fluorescent dye)-stained preparations visualized a fluorescence microscope. long-term effect + its components lines observed inverted phase contrast microscopy. In MTT test (cell viability assay), complex produced more potent (HeLa, OS143B) comparison that after separate treatment cPt. At same time, action rather small On other hand, another CPP cPt, i.e., without significant line (OS143B). images fluorescent microscopy showed TAMRA-TP10 interior HeLa cells. case TAMRA-PTD4 only first compound found inside line. contrast, none compounds gained access cells (HEK293, HEL299). Long-term incubation (estimated by microscopy) lead an enhanced (decrease number change morphology) compared each single agent. With regard CPPs, improved if both form complex. Additionally, relatively safe for What is more, also